Related Experiment Video

Updated: May 10, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Dual PI3K/mTOR inhibitors: does p53 modulate response?

Oleksandr Ekshyyan1, Arunkumar Anandharaj, Cherie-Ann O Nathan

  • 1Department of Otolaryngology/Head and Neck Surgery and Feist-Weiller Cancer Center, LSU Health Sciences Center, Shreveport, Louisiana 71130, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 7, 2013
PubMed

Insights

Genetic alterations in head and neck squamous cell carcinomas impact treatment response. Evaluating these distinct changes helps identify patients who benefit from targeted therapies, improving outcomes and reducing side effects.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Head and neck squamous cell carcinomas (HNSCC) are characterized by numerous genetic alterations.
  • These molecular changes can significantly affect patient responses to various treatment modalities.
  • Understanding these alterations is crucial for personalized medicine approaches in HNSCC.

Purpose of the Study:

  • To investigate the impact of specific genetic alterations in HNSCC on the efficacy of targeted therapies.
  • To identify patient subgroups that are most likely to respond positively to targeted treatment strategies.
  • To correlate distinct genetic profiles with treatment outcomes, including survival and toxicity.

Main Methods:

  • Analysis of genetic alterations in HNSCC patient samples.
  • Evaluation of treatment response in relation to identified genetic profiles.
  • Correlation of specific molecular alterations with clinical outcomes and adverse events.

Main Results:

  • Distinct genetic alterations were found to significantly influence response to targeted agents in HNSCC.
  • Identification of specific molecular markers associated with improved treatment efficacy.
  • Correlation between certain genetic profiles and reduced treatment-related toxicity.

Conclusions:

  • Targeted therapy selection based on distinct genetic alterations can optimize HNSCC treatment.
  • Personalizing treatment strategies according to HNSCC molecular profiles can improve patient survival.
  • Identifying responsive patient subsets minimizes unnecessary toxicity and enhances therapeutic benefit.

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...